Dated 01 April 2011 PRIMA BIOMED LTD (ABN 90 009 237 889) And CELL THERAPIES PTY LTD (ABN 15 100 285 916) MASTER SERVICES AGREEMENTMaster Services Agreement • October 3rd, 2012 • Prima BioMed LTD • Pharmaceutical preparations • Victoria
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Executive- and Business Manager Employment Contract Between Prima Biomed GmbH Deutscher Platz 5E 04103 Leipzig (hereinafter, known as “Corporation”) And Mr. Marc Voigt Stubenrauchstr. 49 12161 Berlin (hereinafter, known as “Mr. Voigt” or...Prima BioMed LTD • October 3rd, 2012 • Pharmaceutical preparations
* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED....Prima BioMed LTD • October 3rd, 2012 • Pharmaceutical preparations
This Project is to take place in member states of the European Union and non-EU states in Europe. The Project is part of a global multi-center phase 2/3 clinical trial of CVacTM -titled as “CANVAS”- sponsored by Prima BioMed Ltd., Australia. Prima is the legal representative of the Sponsor according to § 40 Para 1 No. 1 German Drug Act (Arzneimittelgesetz- AMG) and the coordinating Partner for the Project.
EMPLOYMENT AGREEMENTEmployment Agreement • October 3rd, 2012 • Prima BioMed LTD • Pharmaceutical preparations • North Carolina
THIS EMPLOYMENT AGREEMENT (“Agreement”), effective as of June 1, 2011 (the “Effective Date”), is made by and between PRIMA BIOMED USA, INC., a Delaware corporation, with its principal place of business located at 2500 Regency Parkway, Cary, NC 27518 USA (“PRIMA”), and SHARRON GARGOSKY, PHD, with a current principal residence of 2833 NW Cumberland Rd, Portland, OR 97210 USA (“Employee”).
